Market Overview:
The global metastatic bone disease market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, rising awareness about metastatic bone diseases, and technological advancements in the field of oncology. Based on type, the global metastatic bone disease market is segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment dominates the global market owing to the high adoption rate of medications for treating metastatic bone diseases. By application, hospitals account for a major share of the global market due to increased spending on healthcare by governments and private players alike. However, clinics are expected to witness higher growth during the forecast period owing to rising demand for outpatient services across regions.
Product Definition:
Metastatic Bone Disease is the spread of cancer cells from a tumor in one part of the body to bones elsewhere in the body. The cancer cells attach to and grow into the bone, weakening it and causing pain. Metastatic Bone Disease can also make bones more likely to break.
Medication:
Metastatic bone disease is a progressive disorder caused by the spread of cancer from the original tumor to other parts of the body. The most common sites for metastasis are lung, liver, and bones.
Radiation Therapy:
Radiation therapy is a form of alternative or second line treatment for patients who have received one or more lines of chemotherapy with no satisfactory results. Radiation oncology treatments are used in the management and treatment of various cancers such as skin, breast, lung, prostate and other non-Hodgkin lymphomas.
Application Insights:
The others application segment held the largest share of revenue in 2016. This can be attributed to the increasing number of patients opting for non-surgical and minimally invasive treatment options. Minimally invasive surgeries involve low risk, short duration of hospitalization and recovery time is less as compared to conventional surgeries. Thus, metastic bone disease has a wide scope in clinics as well as hospitals which contributes towards a significant market share.
However, hospitals are expected to dominate the overall market over the forecast period owing to factors such as large patient base with high unmet medical needs resulting from traveling & moving abroad for employment or studies coupled with rising incidences due to genetic disorders & cancer worldwide including India, China & Japan which boosts product demand there every year since past few years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate of advanced therapeutics are some factors responsible for its dominance. In addition, increasing prevalence of bone metastases is also expected to drive the regional growth over the forecast period. For instance, as per a recent study published by National Cancer Institute (NCI), in 2018 about 2 million people will be diagnosed with cancer in United States and around 600 thousand people will die due to this disease every year.
Growth Factors:
- Increasing incidence of cancer: The incidence of cancer is increasing at an alarming rate across the globe. This is one of the major growth drivers for metastatic bone disease market as a large number of patients are diagnosed with metastatic bone disease every year.
- Rising awareness about metastatic bone disease: There is a growing awareness among people about metastatic bone disease and its symptoms. This is helping to increase the diagnosis rate for this condition, thereby driving the growth of the market.
- Advances in treatment options: The treatment options for metastatic bone disease are evolving rapidly with new and innovative therapies being developed constantly. This is providing patients with more choices and helping to drive market growth further.
- Growing aging population: The global population is aging rapidly and this trend is particularly prominent in developed countries such as Japan, USA, etc., where there exists a high prevalence of elderly people who are at risk for developing metastatic bone diseases due to their age-related health conditions such as cancer, osteoporosis, etc,. Thus, there exists a large potential patient pool that can be targeted by players operating in this market space thereby driving its growth further.. 5) Increasing healthcare expenditure: Healthcare expenditure around the world has been increasing steadily over past few years due to rising income levels and improving healthcare infrastructure globally
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Bone Disease Market Research Report
By Type
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
By Application
Hospitals, Clinics, Others
By Companies
Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Bone Disease Market Report Segments:
The global Metastatic Bone Disease market is segmented on the basis of:
Types
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Merck & Co
- Roche
- Novartis
- Eli Lilly and Company
- Bayer
- Fresenius Kabi
- BTG plc
- Boston Scientific
- Medtronic
Highlights of The Metastatic Bone Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Radiation Therapy
- Surgical Intervention
- Tumor Ablation Therapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Bone Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic bone disease is a condition in which cancer cells spread from the original tumor to other parts of the body. This can happen either through direct invasion (when cancer cells break through the skin and enter the bloodstream) or by traveling along blood vessels (metastasis). Once metastatic bone disease occurs, it can be very difficult to treat.
Some of the major players in the metastatic bone disease market are Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic.
The metastatic bone disease market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Bone Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Bone Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Bone Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Bone Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Bone Disease Market Size & Forecast, 2018-2028
4.5.1 Metastatic Bone Disease Market Size and Y-o-Y Growth
4.5.2 Metastatic Bone Disease Market Absolute $ Opportunity
Chapter 5 Global Metastatic Bone Disease Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metastatic Bone Disease Market Size Forecast by Type
5.2.1 Medication
5.2.2 Radiation Therapy
5.2.3 Surgical Intervention
5.2.4 Tumor Ablation Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metastatic Bone Disease Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metastatic Bone Disease Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Bone Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Bone Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metastatic Bone Disease Analysis and Forecast
9.1 Introduction
9.2 North America Metastatic Bone Disease Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metastatic Bone Disease Market Size Forecast by Type
9.6.1 Medication
9.6.2 Radiation Therapy
9.6.3 Surgical Intervention
9.6.4 Tumor Ablation Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metastatic Bone Disease Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metastatic Bone Disease Analysis and Forecast
10.1 Introduction
10.2 Europe Metastatic Bone Disease Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metastatic Bone Disease Market Size Forecast by Type
10.6.1 Medication
10.6.2 Radiation Therapy
10.6.3 Surgical Intervention
10.6.4 Tumor Ablation Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metastatic Bone Disease Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metastatic Bone Disease Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metastatic Bone Disease Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metastatic Bone Disease Market Size Forecast by Type
11.6.1 Medication
11.6.2 Radiation Therapy
11.6.3 Surgical Intervention
11.6.4 Tumor Ablation Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metastatic Bone Disease Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metastatic Bone Disease Analysis and Forecast
12.1 Introduction
12.2 Latin America Metastatic Bone Disease Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metastatic Bone Disease Market Size Forecast by Type
12.6.1 Medication
12.6.2 Radiation Therapy
12.6.3 Surgical Intervention
12.6.4 Tumor Ablation Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metastatic Bone Disease Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metastatic Bone Disease Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metastatic Bone Disease Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metastatic Bone Disease Market Size Forecast by Type
13.6.1 Medication
13.6.2 Radiation Therapy
13.6.3 Surgical Intervention
13.6.4 Tumor Ablation Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metastatic Bone Disease Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Bone Disease Market: Competitive Dashboard
14.2 Global Metastatic Bone Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Merck & Co
14.3.3 Roche
14.3.4 Novartis
14.3.5 Eli Lilly and Company
14.3.6 Bayer
14.3.7 Fresenius Kabi
14.3.8 BTG plc
14.3.9 Boston Scientific
14.3.10 Medtronic
